Investigation of the pronounced synergism between prostaglandin E2 and other constrictor agents on rat femoral artery

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 74, Issue 6, 2006, Pages 401-415

  Hung, Gloria H Y ^a   Jones, Robert Leslie ^b   Lam, Francis F Y ^a   Chan, Kam Ming ^a   Hidaka, Hiroyoshi ^c   Suzuki, Masaaki ^d   Sasaki, Yasuharu ^e  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c D Western Therapeutics Institute   (Japan)

^d GIFU UNIVERSITY   (Japan)

^e KITASATO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 17 PHENYL OMEGA TRINOR PROSTAGLANDIN E2; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 5 BROMO 2 METHOXY N [3 (NAPHTHALEN 2 YL METHYLPHENYL)ACRYLOYL] BENZENESULPHONAMIDE; CALCIUM ION; H 1152; L 798106; METHYL 7 [2BETA [6 (1 CYCLOPENTEN 1 YL) 4R HYDROXY 4 METHYL 1E,5E HEXADIENYL] 3ALPHA HYDROXY 5 OXO 1R,1ALPHA CYCLOPENTYL] 4Z HEPTENOATE; NIFEDIPINE; PHENYLEPHRINE; POTASSIUM ION; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTAGLANDIN E3; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; RHO KINASE; RHO KINASE INHIBITOR; SC 51322; SULPROSTONE; UNCLASSIFIED DRUG; VASOCONSTRICTOR AGENT;

ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; BIOCHEMICAL COMPOSITION; CALCIUM TRANSPORT; CONTROLLED STUDY; DRUG SELECTIVITY; FEMORAL ARTERY; GENETIC TRANSDUCTION; GUINEA PIG; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ALPROSTADIL; ANIMALS; DINOPROSTONE; DRUG INTERACTIONS; DRUG SYNERGISM; FEMORAL ARTERY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NIFEDIPINE; PHENYLEPHRINE; POTASSIUM; PROSTAGLANDINS F, SYNTHETIC; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PROSTAGLANDIN; RECEPTORS, PROSTAGLANDIN E; SENSITIVITY AND SPECIFICITY; VASOCONSTRICTOR AGENTS;

EID: 33744549867     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2006.04.002     Document Type: Article

References (62)

1. 2. Am. J. Physiol. 277 (1999) H924-H930
2. Kennedy C., Zhang Y., Brandon S., et al. Hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat. Med. 5 (1999) 217-220
3. 2 receptors. Hypertension 35 (2000) 1129-1134
4. 3-receptor agonists on human isolated pulmonary artery. Br. J. Pharmacol. 113 (1994) 369-374
5. 3-receptor in guinea-pig aorta: partial agonist action of the non-prostanoid ONO-AP-324. Br. J. Pharmacol. 125 (1998) 1288-1296
6. 1 receptors in pig and rabbit blood vessels. Br. J. Pharmacol. 134 (2001) 313-324
7. Savage M.A., Moummi C., Karabotsos P.J., et al. SC-46275: a potent and highly selective agonist at the EP3 receptor. Prost. Leukot. Essent. Fatty Acids 49 (1993) 939-943
8. Tsai B.S., Keith R.H., Perkins W.E., et al. Preferential binding of the prostaglandin SC-46275 to canine gastric versus intestinal receptors. J. Pharmacol. Exp. Ther. 275 (1995) 368-373
9. 2-sensitive receptors. Adv. Prostaglandin Thromboxane Leukot. Res. 17A (1987) 467-470
10. Lawrence R.A., Jones R.L., and Wilson N.H. Characterization of receptors involved in the direct and indirect actions of prostaglandins E and I on the guinea-pig ileum. Br. J. Pharmacol. 105 (1992) 271-278
11. 2 antagonist and analgesic. Bioorg. Med. Chem. Lett. 4 (1994) 509-514
12. 2 antagonist. Bioorg. Med. Chem. 9 (2001) 1-6
13. 3 prostanoid receptor. Bioorg. Med. Chem. 9 (2001) 1977-1984
14. 3-subtype. Br. J. Pharmacol. 141 (2004) 600-609
15. Uehata M., Ishizaki T., Satoh H., et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389 (1997) 990-994
16. Sasaki Y., Suzuki M., and Hidaka K. The novel and specific rho-kinase inhibitor ((S)(+)-2-methyl-1-[(4-methyl-5-isoquinolyl)sulphonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol. Ther. 93 (2002) 225-232
17. 3 receptor agonists. Br. J. Pharmacol. 139 (2003) 1449-1461
18. Matsumura Y., Kita S., and Okui T. Mechanisms of endothelin-induced potentiation of noradrenaline response in rat mesenteric artery. Clin. Exp. Pharmacol. Physiol. 28 (2001) 540-544
19. Wingard C.J., Husain S., Williams J., et al. RhoA-Rho kinase mediates synergistic ET-1 and phenylephrine contraction of rat corpus cavernosum. Am. J. Physiol. 285 (2003) R1145-R1152
20. 2 blocking drug on platelets and vascular and airways smooth muscle in vitro. Br. J. Pharmacol. 97 (1989) 783-794
21. Glass G.V., and Hopkins K.D. Multiple comparisons and trend analysis. Statistical Methods in Education and Psychology (1995), Allyn and Bacon, Boston 444-481
22. Dorn G.W., Becker M.W., and Davis M.G. Dissociation of the contractile and hypertrophic effects of vasoconstrictor prostanoids in vascular smooth muscle. J. Biol. Chem. 267 (1992) 24897-24905
23. Jones R.L., Peesapati V., and Wilson N.H. Antagonism of the thromboxane-sensitive contractile systems of rabbit aorta, dog saphenous vein and guinea-pig trachea. Br. J. Pharmacol. 76 (1982) 423-438
24. Baxter G.S., Clayton J.K., Coleman R.A., et al. Characterization of the prostanoid receptors mediating constriction and relaxation of human isolated uterine artery. Br. J. Pharmacol. 116 (1995) 1692-1696
25. 2 in rat femoral artery preparations in vivo and in vitro. Arch. Int. Pharmacodyn. Ther. 325 (1993) 70-85
26. 2 (arbaprostil) in rat femoral arterial preparations in vivo and in vitro. Gen. Pharmacol. 24 (1993) 1185-1193
27. Durocher Y., Perret S., Thibadeau E., et al. A reporter gene assay for high-throughput screening of G-protein-coupled receptors stably or transiently expressed in HEK293 EBNA cells grown in suspension culture. Anal. Biochem. 284 (2000) 316-326
28. 1) receptor agonist-induced DNA synthesis and proliferation in primary cultures of adult rat hepatocytes: the involvement of TGF-α. Endocrinology 142 (2001) 4428-4440
29. 2 inhibits spontaneous postsynaptic currents in rat supraoptic neurones via presynaptic EP receptors. J. Neuroendocrinol. 11 (1999) 879-886
30. Abramovitz M., Adam M., Boie Y., et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim. Biophys. Acta 1483 (2000) 285-293
31. 2 prostanoid receptor subtypes. Eur. J. Pharmacol. 340 (1997) 227-241
32. Kiriyama M., Ushikubi F., Kobayashi T., et al. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol. 122 (1997) 217-224
33. Tsai B.S., Kessler L.K., Stolzenbach J., et al. Expression of gastric antisecretory and prostaglandin E receptor binding activity of misoprostol free acid. Dig. Dis. Sci. 36 (1991) 588-593
34. Chang C.S., Negishi M., Nakano T., et al. 7,7-Difluoroprostacyclin derivative, AFP-07, a highly selective and potent agonist for the prostacyclin receptor. Prostaglandins 53 (1997) 83-90
35. 4 receptors using GW 627368 and taprostene: evidence for species differences. Prost. Leukot. Essent. Fatty Acids 74 (2005) 289-299
36. 3 preparation. Fund. Clin. Pharmacol. 15 Suppl. 1 (2001) 69
37. Cao J., Shayibuzhati M., Tajima T., et al. In vitro pharmacological characterization of the prostanoid receptor population in the non-pregnant porcine myometrium. Eur. J. Pharmacol. 442 (2002) 115-123
38. 1B/1D receptor-mediated contraction of the rabbit isolated renal artery. Br. J. Pharmacol. 130 (2000) 835-842
39. 2-receptor agonist, U-46619. Br. J. Pharmacol. 110 (1993) 360-368
40. Breyer M.D., and Breyer R.M. G-protein-coupled prostanoid receptors and the kidney. Annu. Rev. Physiol. 63 (2001) 579-603
41. Katoh H., Negishi M., and Ichikawa A. Prostaglandinn E receptor EP3 subtype induces neurite retraction via a small GTPase Rho. J. Biol. Chem. 271 (1996) 29780-29784
42. Katoh H., Aoki J., Ichikawa A., et al. p160 RhoA-binding kinase ROKalpha induces neurite retraction. J. Biol. Chem. 273 (1998) 2489-2492
43. 2+-dependent activation of Rho and Rho kinase in membrane depolarization-induced and receptor-stimulation-induced vascular smooth muscle contraction. Circ. Res. 93 (2003) 548-556
44. Mita M., Yanagihara H., Hishinuma S., et al. Membrane-depolarization-induced contraction of rat caudal arterial muscle involves Rho-associated kinase. Biochem. J. 364 (2002) 431-440
45. Asano M., and Nomura Y. Comparison of inhibitory effects of Y-27632, a Rho-kinase inhibitor, in strips of small and large arteries from spontaneously hypertensive and normotensive Wistar-Kyoto rats. Hypertens. Res. 26 (2003) 97-106
46. Buyukufsar K., Levent A., and Ark M. Expression of Rho-kinase and its functional role in the contractile activity of the mouse vas deferens. Br. J. Pharmacol. 140 (2003) 743-749
47. Ghisdal P., Vandenberg G., and Morel N. Rho-dependent kinase is involved in agonist-activated calcium entry in rat arteries. J. Physiol. 551 (2003) 855-867
48. +-induced contraction by the ROCKs inhibitor Y-27632 in vascular smooth muscle: possible involvement of ROCKs in a signal transduction pathway. J. Pharmacol. Sci. 92 (2003) 56-69
49. 2+ sensitization of arterial muscle. Am. J. Physiol. 285 (2003) 1377-1385
50. 2+-dependent and -independent mechanisms. J. Physiol. 560 (2004) 839-855
51. Kamm K.E., and Stull J.T. The function of myosin and myosin light chain kinase phosphorylation in smooth muscle. Annu. Rev. Pharmacol. Toxicol. 25 (1985) 593-620
52. Somlyo A.P., and Somlyo A.V. Signal transduction by G-proteins, Rho-kinase and protein phosphatase to smooth muscle and non-smooth muscle myosin II. J. Physiol. 522 (2000) 177-185
53. 2+ sensitization of smooth muscle. Proc. Natl. Acad. Sci. USA 93 (1996) 1340-1345
54. 2+ sensitization of smooth muscle. FEBS Lett. 440 (1998) 183-187
55. Batchelor T.J.P., Sadaba J.R., and Ishola A. Rho-kinase inhibitors prevent agonist-induced vasospasm in human internal mammary artery. Br. J. Pharmacol. 132 (2001) 302-308
56. 2+ sensitization and mobilization by MCh in tracheal smooth muscle. Am. J. Physiol. 280 (2001) L1218-L1224
57. 2-Adrenoceptor agonists enhance responses to certain other vasoconstrictor agents in rat tail artery. Br. J. Pharmacol. 96 (1989) 539-546
58. Wahlestedt C., Hakanson R., Vaz C.A., et al. Norepinephrine and neuropeptide Y: vasoconstrictor cooperation in vivo and in vitro. Am. J. Physiol. 258 (1990) R736-R742
59. 2 receptor-mediated contraction of the rabbit isolated femoral artery. Br. J. Pharmacol. 10 (1992) 418-421
60. Lew M.J., and Flanders S. Mechanisms of melatonin-induced vasoconstriction in the rat tail artery: a paradigm of weak vasoconstriction. Br. J. Pharmacol. 126 (1999) 1408-1418
61. Yildiz O., Smith J.R., and Purdy R.E. Serotonin and vasoconstrictor synergism. Life Sci. 62 (1998) 1723-1732
62. Hamberg M., Svensson J., and Samuelsson B. Prostaglandin endoperoxides. A new concept concerning the mode of action and release of prostaglandins. Proc. Natl. Acad. Sci. USA 71 (1974) 3824-3828